Summary: After the S&P rebounded nicely from its September/October low, it seems that solid value
Summary: The COVID-19 pandemic made Pfizer the most recognizable pharmaceutical company on the planet. But,
Summary: PFE has underperformed the S&P 500 after forming its December highs. The market is
Summary: PFE has dropped on concerns about post-COVID growth prospects. The company has an aggressive
Summary: Pfizer held an R&D day this week where it discussed its broad pipeline. There
Summary: Pfizer has a history of performing well during recessions and bear markets on Wall
Summary: Pfizer’s net income was $8,609 million in Q3 2022, up 5.7% year-on-year. The number
Summary: Pfizer demonstrates its leadership in the COVID franchise as it upgraded its FY22 guidance.
Summary: Pfizer released its Q3 2022 earnings on 1st November. PFE had another blockbuster quarter,
Summary: Get ahead of the market by subscribing to Seeking Alpha’s Stocks to Watch, a